Diffuse large B-cell lymphoma with concurrent high MYC and BCL2 expression shows evidence of active B-cell receptor signaling by quantitative immunofluorescence.
B-cell receptor (BCR)-mediated signaling plays an important role in the pathogenesis of a subset of diffuse large B-cell lymphoma (DLBCL), and novel agents targeting this pathway are now in clinical use. We have previously identified a signature of active BCR signaling on formalin-fixed paraffin-emb...
Main Authors: | Agata M Bogusz, Alexandra E Kovach, Long P Le, Derek Feng, Richard H G Baxter, Aliyah R Sohani |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5315400?pdf=render |
Similar Items
-
Diffuse Large B-Cell Lymphoma in Kenya: MYC, BCL2, and the Cell of Origin
by: Jonathan Wawire, et al.
Published: (2019-04-01) -
Primary cutaneous diffuse large B‐cell lymphoma, leg type with MYC/BCL2/BCL6 overexpression
by: Yosuke Okada, et al.
Published: (2022-02-01) -
The survival impact of combined expression of myc, bcl2 and bcl6 in diffuse large b cell lymphoma patients
by: Adelina BIRCEANU COROBEA, et al.
Published: (2018-06-01) -
Neurolymphomatosis in Recrudescent Diffuse Large B-cell Lymphoma
by: Antonio Lopez, et al.
Published: (2023-01-01) -
Copy Number Alteration and Mutational Profile of High-Grade B-Cell Lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> Rearrangements, Diffuse Large B-Cell Lymphoma with <i>MYC</i>-Rearrangement, and Diffuse Large B-Cell Lymphoma with <i>MYC</i>-Cluster Amplification
by: Masashi Miyaoka, et al.
Published: (2022-11-01)